2019 Future of Globoid Cell Leukodystrophy R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 2BAAD34C16BEN
VPAResearch

Abstracts

The global demand for Globoid Cell Leukodystrophy treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Globoid Cell Leukodystrophy pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Globoid Cell Leukodystrophy pipeline companies from advancing their products into Phase 3 or Phase 4.

Globoid Cell Leukodystrophy Report Description-

The 2019 pipeline study on Globoid Cell Leukodystrophy pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Globoid Cell Leukodystrophy pipeline compounds.

The Globoid Cell Leukodystrophy pipeline guide presents information on all active drugs currently being developed for Globoid Cell Leukodystrophy. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Globoid Cell Leukodystrophy pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Globoid Cell Leukodystrophy drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Globoid Cell Leukodystrophy product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Globoid Cell Leukodystrophy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Globoid Cell Leukodystrophy pipeline report includes-

• An overview of Globoid Cell Leukodystrophy disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Globoid Cell Leukodystrophy pipeline
• Company wise list of Globoid Cell Leukodystrophy pipeline
• Mechanism of Action wise Globoid Cell Leukodystrophy pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Globoid Cell Leukodystrophy pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Globoid Cell Leukodystrophy pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Globoid Cell Leukodystrophy pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL GLOBOID CELL LEUKODYSTROPHY PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Globoid Cell Leukodystrophy Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Globoid Cell Leukodystrophy pipeline, H1- 2019
3.5 Mechanism of Action wise Globoid Cell Leukodystrophy Pipeline Candidates

4 ADVANCED PHARMACEUTICALS, LLC GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

4.1 Advanced Pharmaceuticals, LLC Business Profile
4.2 Advanced Pharmaceuticals, LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BIOXCEL CORPORATION GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

5.1 BioXcel Corporation Business Profile
5.2 BioXcel Corporation Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 COMMENCE BIO INC GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

6.1 Commence Bio Inc Business Profile
6.2 Commence Bio Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 KYORIN PHARMACEUTICAL CO LTD GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

7.1 Kyorin Pharmaceutical Co Ltd Business Profile
7.2 Kyorin Pharmaceutical Co Ltd Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 MAGENTA THERAPEUTICS INC GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

8.1 Magenta Therapeutics Inc Business Profile
8.2 Magenta Therapeutics Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 RANEDIS PHARMACEUTICALS LLC GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE DETAILS

9.1 Ranedis Pharmaceuticals LLC Business Profile
9.2 Ranedis Pharmaceuticals LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. LATEST GLOBOID CELL LEUKODYSTROPHY DRUG PIPELINE DEVELOPMENTS, 2019

11. APPENDIX

11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information